Rhythm Pharmaceuticals Shares Important Update on FDA Review
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a pioneering biopharmaceutical company committed to revolutionizing the treatment for patients with rare neuroendocrine diseases, has recently made a significant announcement regarding its product IMCIVREE (setmelanotide). The company confirmed that the U.S. Food and Drug Administration (FDA) has extended the review period of their supplemental New Drug Application (sNDA) for IMCIVREE, originally set for December 20, 2025, to a new goal date of March 20, 2026.
Details on the FDA's Review Extension
This extension, which comes after a request from the FDA for further sensitivity analyses of clinical efficacy data from Rhythm's Phase 3 trial focused on acquired hypothalamic obesity, aims to provide additional insights without requesting new data. The FDA deemed this request a 'major amendment', allowing more time for their review process. Notably, this amendment does not involve any new information related to the safety or manufacturing processes of setmelanotide.
Insights from Company Leadership
David Meeker, M.D., the Chairman and CEO of Rhythm, expressed optimism regarding the product's profile, stating, "Setmelanotide has demonstrated a compelling product profile, and we have every confidence that these additional sensitivity analyses will reinforce the strength of the data and confirm the potential benefits for patients suffering from hypothalamic obesity." He emphasized the company's ongoing collaboration with the FDA review team as they work to bring this innovative solution to a patient population that has few, if any, treatment options available for their condition.
Upcoming Conference Call Announcement
Rhythm Pharmaceuticals will conduct a live conference call and webcast today at 8:00 a.m. ET to discuss the extension of the FDA's review period. Attendees are encouraged to register for the call in advance and should look for the webcast under the 'Events and Presentations' section of Rhythm Pharmaceuticals' website.
About Rhythm Pharmaceuticals
As a commercial-stage biopharmaceutical company, Rhythm focuses on the lives of patients with rare neuroendocrine diseases. The company's lead product, IMCIVREE (setmelanotide), is an MC4R agonist approved by the FDA to aid in the reduction of excessive body weight and maintenance of weight loss in both adult and pediatric patients with specific genetic conditions. Abroad, the European Commission and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) have similarly approved setmelanotide for use in addressing hunger and obesity associated with specific genetically confirmed conditions.
Current Indications for Setmelanotide
In the United States, setmelanotide is specifically indicated for individuals two years and older who experience obesity related to Bardet-Biedl syndrome (BBS) and various genetic deficiencies such as POMC, PCSK1, and LEPR, identified through FDA-approved testing. The indications extend to similar patient populations within the European Union and the United Kingdom.
Limitations and Contraindications
However, setmelanotide is not suitable as an intervention for obesity due to benign classifications of POMC, PCSK1, or LEPR deficiencies or for other types of obesity related to genetic conditions that do not fall within its proven efficacy. Prior hypersensitivity reactions to setmelanotide or its components also make patients ineligible for treatment.
Understanding the Safety Profile
The use of setmelanotide does come with important warnings. Patients must be monitored for potential skin changes, sexual arousal disturbances, and psychological effects such as depression and suicidal ideation during treatment. This monitoring is crucial, especially in pediatric populations, where growth may be impacted by significant weight loss. Furthermore, the use of benzyl alcohol in formulations could pose serious risks to neonates and low birthweight infants.
Common Adverse Reactions
Among the most commonly reported adverse reactions (occurring in 20% or more of patients) are skin hyperpigmentation, injection site reactions, and gastrointestinal issues such as nausea and abdominal pain. Due to this safety profile, Rhythm encourages open communication between patients and healthcare providers regarding any concerns that may arise during treatment.
Contact Information for Rhythm Pharmaceuticals
For further inquiries or to report any adverse reactions, stakeholders can contact Rhythm Pharmaceuticals through their Investor Relations team, led by David Connolly. Interested parties can reach him at (857) 264-4280 or via email at dconnolly@rhythmtx.com. For media inquiries, Layne Litsinger of Real Chemistry is available at (410) 916-1035 or at llitsinger@realchemistry.com.
Frequently Asked Questions
What is IMCIVREE?
IMCIVREE (setmelanotide) is a medication designed to treat obesity associated with rare genetic conditions and is approved by the FDA for specific indications.
Why was the FDA review period extended?
The FDA extended the review period to allow for additional sensitivity analyses of previously submitted clinical efficacy data.
What are the common side effects of setmelanotide?
Common side effects include skin hyperpigmentation, nausea, abdominal pain, and injection site reactions, among others.
Who is eligible for treatment with setmelanotide?
Patients aged two and older with specific genetic obesity conditions are eligible for treatment with setmelanotide.
How can I learn more about Rhythm Pharmaceuticals?
For more information, visit the Rhythm Pharmaceuticals website or contact their Investor Relations department directly.
